Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Jiangsu Jingze Biopharmaceutical Co., Ltd.

Clinicaltrial registered2 Nov 2026

Jiangsu Jingze Biopharmaceutical Co., Ltd.

2 Nov 2026: Trial registered · A Study Evaluating the Efficacy and Safety of Recombinant Human Truncated Plasmin Injection (JZB32) in Patients With Vitreomacular Traction. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
2 Nov 2026
Title
A Study Evaluating the Efficacy and Safety of Recombinant Human Truncated Plasmin Injection (JZB32) in Patients With Vitreomacular Traction
Conditions
Vitreomacular Traction (VMT)
Phase
Phase 2
Study Type
Interventional
Status
Recruiting
Countries
China
Country
China
Reference
NCT07910630
Location
China
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Jiangsu Jingze Biopharmaceutical Co., Ltd.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from China

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.